GLAND.NS Balance Sheet
Gland Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹1,558.50 Cr. | ₹3,541.31 Cr. | ₹3,750.54 Cr. | ₹4,051.97 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹177.22 Cr. | ₹237.88 Cr. | ₹150.56 Cr. | ₹342.18 Cr. | CapitalWorkInProgress |
| Goodwill | ₹0.00 Cr. | ₹242.26 Cr. | ₹248.20 Cr. | ₹293.87 Cr. | Goodwill |
| Other Intangible Assets | ₹11.66 Cr. | ₹112.22 Cr. | ₹105.70 Cr. | ₹108.62 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹129.35 Cr. | ₹176.07 Cr. | ₹134.92 Cr. | N/A | OtherNoncurrentAssets |
| Total Non-current Assets | ₹1,876.73 Cr. | ₹5,016.09 Cr. | ₹4,441.98 Cr. | ₹4,984.06 Cr. | NoncurrentAssets |
| Inventories | ₹1,945.30 Cr. | ₹1,655.24 Cr. | ₹1,685.22 Cr. | ₹1,743.89 Cr. | Inventories |
| Trade Receivables | ₹871.39 Cr. | ₹1,558.69 Cr. | ₹1,516.53 Cr. | ₹1,891.38 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹1,908.89 Cr. | ₹357.09 Cr. | ₹2,556.21 Cr. | ₹3,359.11 Cr. | CashAndCashEquivalents |
| Current Investments | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | CurrentInvestments |
| Other Current Assets | ₹247.78 Cr. | ₹339.86 Cr. | ₹531.36 Cr. | ₹458.67 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹6,900.81 Cr. | ₹5,645.15 Cr. | ₹6,782.94 Cr. | ₹7,526.78 Cr. | CurrentAssets |
| Total Assets | ₹8,777.53 Cr. | ₹10,661.25 Cr. | ₹11,224.92 Cr. | ₹12,510.85 Cr. | Assets |
| Equity Share Capital | ₹16.47 Cr. | ₹16.47 Cr. | ₹16.48 Cr. | ₹16.48 Cr. | EquityShareCapital |
| Other Equity | ₹7,942.25 Cr. | ₹8,707.37 Cr. | ₹9,134.26 Cr. | ₹10,341.47 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹7,958.72 Cr. | ₹8,723.84 Cr. | ₹9,150.74 Cr. | ₹10,357.95 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | NonControllingInterest |
| Total Equity | ₹7,958.72 Cr. | ₹8,723.84 Cr. | ₹9,150.74 Cr. | ₹10,357.95 Cr. | Equity |
| Long-term Borrowings | ₹3.26 Cr. | ₹106.54 Cr. | ₹77.66 Cr. | ₹69.92 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹89.68 Cr. | ₹539.04 Cr. | ₹509.33 Cr. | ₹544.50 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.56 Cr. | ₹213.24 Cr. | ₹191.55 Cr. | ₹173.44 Cr. | BorrowingsCurrent |
| Trade Payables | ₹587.35 Cr. | ₹862.69 Cr. | ₹820.41 Cr. | ₹833.87 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹92.47 Cr. | ₹184.92 Cr. | ₹302.26 Cr. | ₹318.48 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹729.13 Cr. | ₹1,398.36 Cr. | ₹1,564.85 Cr. | ₹1,608.40 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹8,777.53 Cr. | ₹10,661.25 Cr. | ₹11,224.92 Cr. | ₹12,510.85 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from GLAND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).